MedPath

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Phase 2
Terminated
Conditions
Neoplasms, Squamous Cell
Carcinoma, Squamous Cell
Carcinoma, Squamous Cell of Head and Neck
Head and Neck Neoplasms
Head and Neck Cancer
Mouth Neoplasms
Interventions
Registration Number
NCT00412776
Lead Sponsor
Sesen Bio, Inc.
Brief Summary

The purpose of this study is to compare the safety and efficacy of Proxinium plus best supportive care with best supportive care only for patients with squamous cell head and neck cancer.

Detailed Description

Head and neck cancer is a general description of a disease that includes several types of soft tissue carcinomas that develop in the head and neck regions.

Proxinium is a recombinant fusion protein that binds to the epithelial cell adhesion molecule (Ep-CAM) that is highly expressed on squamous cell carcinomas of the head and neck (SCCHN). Proxinium is administered via intratumoural injection.

The primary objective of the study is to compare the overall survival time for patients treated with intratumourally injected Proxinium plus BSC versus BSC alone. Secondary objectives of the study include comparison of locoregional tumour control, local progression-free survival, symptomatic benefit and safety profile in patients who receive Proxinium plus BSC versus patients who receive BSC

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
165
Inclusion Criteria

Disease Characteristics

  • The patient must be 18 years of age or older.
  • The patient must have squamous cell carcinoma of the head and neck.
  • The squamous cell carcinoma must be Ep-CAM positive.
  • ECOG performance status of 0, 1, 2 or 3.
  • 12 week life expectancy

Prior/Concurrent Therapy

  • The patient must have received therapy for their primary disease (eg, surgery and/or radiotherapy, chemo-radiotherapy or chemotherapy).
  • The patient must have been diagnosed with persistent or recurrent disease or a second primary tumour.
  • The patient's disease must be refractory.
  • There must be at least 2 weeks between the last dose of chemotherapy or radiotherapy and receiving study drug or 4 weeks between the last dose of an experimental drug and receiving study drug.

Patient Characteristics

  • The patient must have adequate hepatic function [alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN) and bilirubin level ≤1.5 × ULN].
  • The patient must have adequate renal function (serum creatinine < 1.5 × ULN).
  • The patient must have the following hematological values: granulocytes ≥1500/μL, platelets ≥75 000/μL and hemoglobin >8 g/dL.
  • The patient must have prothrombin time and partial thromboplastin time within normal limits.

Other

• Women of childbearing potential and male patients must agree to use a highly effective contraceptive method.

Exclusion Criteria
  • The patient has clinically significant distant metastases.
  • The patient is eligible to have surgical resection or radiotherapy, chemo-radiotherapy or chemotherapy.
  • The patient has a nasopharyngeal tumour.
  • The patient has AIDS, hepatitis C or hepatitis B.
  • The patient has clinically significant renal or hepatic disease.
  • Tumors are prone to bleeding.
  • The patient is pregnant or lactating.
  • The patient requires 'blood thinning' medications and can not safely discontinue the medication.
  • The patient is currently enrolled in another clinical trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1ProxiniumProxinium plus Best Supportive Care
Primary Outcome Measures
NameTimeMethod
SurvivalDeath or 12 months from the date that the last patient required for efficacy analysis has been randomized
Secondary Outcome Measures
NameTimeMethod
Tumour response, safety and quality of lifeDeath or 12 months from the date that the last patient required for efficacy analysis has been randomized

Trial Locations

Locations (122)

Hospital Italiano Regional del Sur

🇦🇷

Bahia Blanca, Argentina

Hospital Municipal de Agudos Leonidas Lucero

🇦🇷

Bahia Blanca, Argentina

Centro de Estudio y Tratamiento de las Enfermedades Neoplasicas (CETEN)

🇦🇷

Buenos Aires, Argentina

Hospital de Clinicas "Jose de San Martin"

🇦🇷

Buenos Aires, Argentina

Hospital Nacional Alejandro Posadas

🇦🇷

Buenos Aires, Argentina

Hospital Universitario Austral

🇦🇷

Buenos Aires, Argentina

Instituto Medico Platense

🇦🇷

La Plata, Argentina

Hospital Italiano Garibaldi

🇦🇷

Rosario, Argentina

Hospital de Câncer de Barretos - Fundação Pio XII

🇧🇷

Barretos, Brazil

Cettro - Centro de Tratamento Oncológico Ltda.

🇧🇷

Brasilia, Brazil

Scroll for more (112 remaining)
Hospital Italiano Regional del Sur
🇦🇷Bahia Blanca, Argentina

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.